Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison – response

Publisher： John Wiley & Sons Inc

E-ISSN： 1442-9071|43|5|497-498

ISSN： 1442-6404

Source： CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol.43, Iss.5, 2015-07, pp. : 497-498

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Injections in retinal vein occlusions

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 42, Iss. 7, 2014-09 ,pp. : 650-655

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison – comment

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 5, 2015-07 ,pp. : 497-497

John Wiley & Sons Inc

Access to resources Recommend Favorite

The 1 year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapy of macular oedema: meta‐analysis

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 42, Iss. 7, 2014-09 ,pp. : 637-649

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intravitreal bevacizumab: a viable treatment for bilateral central retinal vein occlusion with serous macular detachment secondary to Waldenström macroglobulinaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 3, 2015-08 ,pp. : 431-434

John Wiley & Sons Inc

Access to resources Recommend Favorite